Medicus Pharma Ltd. Common Stock (MDCX)

About MDCX

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly kno…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

16

Website

medicuspharma.com

Fundamentals

1-day range

$0.2954$0.3174

Market cap

$16.97M

P/E (trailing)

—

P/E (forward)

-0.62

EPS (trailing)

$-2.63

Dividend yield

—

Beta

-0.48

Avg. volume

1.99M

Forecasts

4 analyst ratings

Medicus Pharma Ltd. Common Stock Competitors

Chosen by industry and closest market cap.

• MDCX

  Medicus Pharma Ltd. Common Stock

  $0.258

  ▼ 3.73%
  Market cap $16.97MP/E —
  $0.25$3.05
• CYCN

  Cyclerion Therapeutics Inc. Common Stock

  $3.81

  ▼ 4.51%
  Market cap $16.67MP/E —
  $1.03$8.48
• OPTH

  Optimi Health Corp. Common Shares

  $4.93

  ▼ 0.80%
  Market cap $16.61MP/E —
  $0.195$11.4
• SKYE

  Skye Bioscience Inc. Common Stock

  $1.81

  ▼ 7.18%
  Market cap $16.58MP/E —
  $1.84$39.92
• LPCN

  Lipocine Inc. Common Stock

  $2.2

  ▼ 1.35%
  Market cap $17.56MP/E —
  $1.81$12.37
• NCEL

  NewcelX Ltd. Ordinary Shares

  $3.19

  ▼ 6.73%
  Market cap $17.98MP/E —
  $1.83$24.6
• MRKR

  Marker Therapeutics Inc. Common Stock

  $1.37

  ▼ 7.12%
  Market cap $18.67MP/E —
  $0.8099$2.46

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Medicus Pharma advances pipeline during Q2 with key milestones
  Yahoo · 8/13/2026
• Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
  Yahoo · 8/12/2026
• Medicus Pharma Q2 EPS $(0.21) Misses $(0.13) Estimate
  Benzinga · 8/12/2026
• Medicus Pharma CMO to lead Antev's Teverelix clinical programme
  Yahoo · 8/3/2026
• Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
  Yahoo · 8/3/2026
• Medicus Pharma targets Gorlin Syndrome with SkinJect - ICYMI
  Yahoo · 8/1/2026
• 12 Health Care Stocks Moving In Friday's After-Market Session
  Benzinga · 7/31/2026
• Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix
  Yahoo · 7/31/2026

• Rodgers Cathy McMorris · June 3, 2026 · Grant

  50.0K
• Raju Ajay · June 3, 2026 · Grant

  50.0K
• Mehmud Faisal · June 3, 2026 · Grant

  250.0K
• May Sara R. · June 3, 2026 · Grant

  50.0K
• Kaiser Larry · June 3, 2026 · Grant

  50.0K
• Ciaruffoli Robert J. · June 3, 2026 · Grant

  50.0K
• Brennan Edward J. · June 3, 2026 · Grant

  25.0K
• Bonner Carolyn F. · June 3, 2026 · Grant

  250.0K
• FISHMAN BARRY · June 3, 2026 · Grant

  50.0K
• Bokhari Raza · June 3, 2026 · Grant

  500.0K
• Ashton William · June 3, 2026 · Grant

  50.0K
• Smith Andrew Alasdair · June 3, 2026 · Grant

  200.0K
• MAHAFFY PATRICK J · June 3, 2026 · Grant

  50.0K
• Raju Ajay · March 30, 2026 · Grant

  25.0K
• Rodgers Cathy McMorris · March 30, 2026 · Grant

  25.0K

Institutional Ownership

March 31, 2026

Total shares held

2.32M

Total value held

$6.44M

Institutional holders

21